The Influence of Visceral Adiposity on Overall Survival: Exploring “Obesity Paradox” Among Hepatocellular Carcinoma Patients Who Receiving Immunotherapy

References

• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63(1):131–140. doi:10.1016/j.jhep.2015.02.031
   PubMed Web of Science ®Google Scholar
• Lysaght J. The ‘obesity paradox’ in action with cancer immunotherapy. Nat Rev Endocrinol. 2019;15(3):132–133. doi:10.1038/s41574-019-0161-2
   PubMed Web of Science ®Google Scholar
• O’Connell F, O’Sullivan J. Help or hindrance: the obesity paradox in cancer treatment response. Cancer Lett. 2021;522:269–280. doi:10.1016/j.canlet.2021.09.021
   PubMed Web of Science ®Google Scholar
• Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141–151. doi:10.1038/s41591-018-0221-5
   PubMed Web of Science ®Google Scholar
• Lee JH, Hyung S, Lee J, Choi SH. Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study. J Immunother Cancer. 2022;10(8):e005226. doi:10.1136/jitc-2022-005226
   PubMed Web of Science ®Google Scholar
• Item F, Konrad D. Visceral fat and metabolic inflammation: the portal theory revisited. Obes Rev. 2012;13(2):30–39. doi:10.1111/j.1467-789X.2012.01035.x
   PubMedGoogle Scholar
• Perna S, Guido D, Grassi M, Rondanelli M. Association between muscle mass and adipo-metabolic profile: a cross-sectional study in older subjects. Clin Interv Aging. 2015;10:499–504. doi:10.2147/CIA.S67872
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Tan KC. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163. doi:10.1016/S0140-6736(03)15268-3
   PubMed Web of Science ®Google Scholar
• Hilmi M, Jouinot A, Burns R, et al. Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology. Pharmacol Ther. 2019;196:135–159. doi:10.1016/j.pharmthera.2018.12.003
   PubMed Web of Science ®Google Scholar
• Chen BB, Liang PC, Shih TT, et al. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. Eur Radiol. 2023;33(1):512–522. doi:10.1007/s00330-022-08980-4
   PubMed Web of Science ®Google Scholar
• Barbi J, Patnaik SK, Pabla S, et al. Visceral obesity promotes lung cancer progression-toward resolution of the obesity paradox in lung cancer. J Thorac Oncol. 2021;16(8):1333–1348. doi:10.1016/j.jtho.2021.04.020
   PubMed Web of Science ®Google Scholar
• Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. 2020;6(4):512–518. doi:10.1001/jamaoncol.2019.5241
   PubMed Web of Science ®Google Scholar
• Fang S, Wang Y, Dang Y, et al. Association between body mass index, C-reactive protein levels, and melanoma patient outcomes. J Invest Dermatol. 2017;137(8):1792–1795. doi:10.1016/j.jid.2017.04.007
   PubMed Web of Science ®Google Scholar
• Shams-White MM, Brockton NT, Mitrou P, et al. Operationalizing the 2018 world cancer research fund/American Institute for cancer research (WCRF/AICR) cancer prevention recommendations: a standardized scoring system. Nutrients. 2019;11(7):1572. doi:10.3390/nu11071572
   PubMed Web of Science ®Google Scholar
• Mormile R. Metformin and lung cancer: the final blow to the obesity paradox. J Thorac Oncol. 2018;13(4):e65–e66. doi:10.1016/j.jtho.2017.11.114
   PubMed Web of Science ®Google Scholar
• Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–135. doi:10.1016/j.metabol.2018.11.001
   PubMed Web of Science ®Google Scholar
• Boura P, Loukides S, Grapsa D, Achimastos A, Syrigos K. The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives. Future Oncol. 2015;11(15):2193–2203. doi:10.2217/fon.15.96
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–322. doi:10.1016/S1470-2045(18)30078-0
   PubMed Web of Science ®Google Scholar
• He M, Chen ZF, Zhang L, et al. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. J Immunother Cancer. 2023;11(6):e007054. doi:10.1136/jitc-2023-007054
   PubMed Web of Science ®Google Scholar
• Vithayathil M, D’Alessio A, Fulgenzi C, et al. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. Hepatol Int. 2023;17(4):904–914. doi:10.1007/s12072-023-10491-3
   PubMed Web of Science ®Google Scholar
• Naik GS, Waikar SS, Johnson A, et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019;7(1):89. doi:10.1186/s40425-019-0512-5
   PubMed Web of Science ®Google Scholar
• Tu X, Yang J, Zheng Y, et al. Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: a real-world study. Int Immunopharmacol. 2022;113(Pt B):109401. doi:10.1016/j.intimp.2022.109401
   PubMedGoogle Scholar
• Jost-Brinkmann F, Demir M, Wree A, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort. Aliment Pharmacol Ther. 2023;57(11):1313–1325. doi:10.1111/apt.17441
   PubMed Web of Science ®Google Scholar
• Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–363. doi:10.1016/j.jhep.2021.09.035
   PubMed Web of Science ®Google Scholar